These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209 [TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Türktaş H; Unsal M; Tülek N; Orüç O Tuber Lung Dis; 1994 Feb; 75(1):58-60. PubMed ID: 8161767 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369 [TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Chang KC; Leung CC; Yew WW; Lau TY; Tam CM Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355 [TBL] [Abstract][Full Text] [Related]
6. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946 [TBL] [Abstract][Full Text] [Related]
7. Liver injury during antituberculosis treatment: an 11-year study. Døssing M; Wilcke JT; Askgaard DS; Nybo B Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249 [TBL] [Abstract][Full Text] [Related]
8. Antituberculosis drugs and hepatotoxicity. Yew WW; Leung CC Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297 [TBL] [Abstract][Full Text] [Related]
9. Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity. Coca NS; Oliveira MS; Voieta I; Antunes CM; Lambertucci JR Rev Soc Bras Med Trop; 2010; 43(6):624-8. PubMed ID: 21181011 [TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. Singh J; Garg PK; Tandon RK J Clin Gastroenterol; 1996 Apr; 22(3):211-4. PubMed ID: 8724260 [TBL] [Abstract][Full Text] [Related]
11. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055 [TBL] [Abstract][Full Text] [Related]
12. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis]. Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910 [TBL] [Abstract][Full Text] [Related]
13. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis]. de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332 [TBL] [Abstract][Full Text] [Related]
19. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035 [TBL] [Abstract][Full Text] [Related]
20. Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. Ichai P; Saliba F; Antoun F; Azoulay D; Sebagh M; Antonini TM; Escaut L; Delvart V; Castaing D; Samuel D Liver Transpl; 2010 Oct; 16(10):1136-46. PubMed ID: 20879012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]